Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 3/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258775 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL1627056 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL1625330 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL1626572 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL7258771 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL1624903 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL1625494 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL1624904 | 0.82 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL3951461 | 0.80 | CRBN (0.46) | SMN1; SMN2TP53MAPTCRBNKMT2A | |
| SCHEMBL5520760 | 0.80 | TP53 (0.51) | SMN1; SMN2TP53MAPTCRBNKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | SMN1; SMN2 3726/4885TP53 4291/4885MAPT 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.